Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
| No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
| 1 | African trypanosomiasis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 2 | AGE-RAGE signaling pathway in diabetic complications |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 3 | Alzheimer disease |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 4 | Amoebiasis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 5 | Antifolate resistance |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 6 | C-type lectin receptor signaling pathway |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 7 | Chagas disease (American trypanosomiasis) |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 8 | Cytokine-cytokine receptor interaction |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 9 | Cytosolic DNA-sensing pathway |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 10 | Fluid shear stress and atherosclerosis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 11 | Graft-versus-host disease |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 12 | Hematopoietic cell lineage |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 13 | Herpes simplex virus 1 infection |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 14 | Human cytomegalovirus infection |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 15 | IL-17 signaling pathway |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 16 | Inflammatory bowel disease (IBD) |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 17 | Inflammatory mediator regulation of TRP channels |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 18 | Influenza A |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 19 | Legionellosis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 20 | Leishmaniasis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 21 | Malaria |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 22 | MAPK signaling pathway |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 23 | Measles |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 24 | Necroptosis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 25 | NF-kappa B signaling pathway |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 26 | NOD-like receptor signaling pathway |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 27 | Non-alcoholic fatty liver disease (NAFLD) |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 28 | Osteoclast differentiation |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 29 | Pathogenic Escherichia coli infection |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 30 | Pertussis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 31 | Prion diseases |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 32 | Rheumatoid arthritis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 33 | Salmonella infection |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 34 | Shigellosis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 35 | Th17 cell differentiation |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 36 | TNF signaling pathway |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 37 | Toll-like receptor signaling pathway |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 38 | Tuberculosis |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 39 | Type I diabetes mellitus |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
| 40 | Yersinia infection |
[1] IL1B | D09315 | Canakinumab | [9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |